Literature DB >> 2149669

T lymphocytes can mediate lysis of autologous melanoma cells by multiple mechanisms: evidence with a single T cell clone.

A Mazzocchi1, A Anichini, C Castelli, M Sensi, F Poli, C Russo, G Parmiani.   

Abstract

The specificity analysis of a CD3+, WT31+, CD8+ cytotoxic T lymphocyte (CTL) clone (CTL 49), isolated from peripheral blood lymphocytes of a melanoma patient (no. 665) after mixed lymphocyte culture with an HLA-A2+ allogeneic lymphoblastoid cell line (VSKB-LCL), revealed that CTL 49 could lyse, in addition to HLA-A2+ lines, autologous HLA-A2- melanoma (Me665/2) and K562 targets. Killing of VSKB-LCL, but not of Me665/2, could be inhibited by anti-CD3 and by anti-HLA-A2 antibodies or by modulation of the CD3 complex. Cold-target competition studies showed that K562, but not VSKB-LCL, could compete with Me665/2 for lysis by CTL 49. However, unlike K562, Me665/2 could be lysed by CTL 49 in a Ca2(+)-independent fashion in 4 h and 18 h assays. CTL 49 expressed mRNA specific for tumor necrosis factor (TNF alpha) and, to a lesser extent, for lymphotoxin (TNF beta). Exposure of the clone to anti-CD3 antibodies induced the expression of interferon(IFN)-gamma-specific mRNA. Antibodies to TNF alpha, TNF beta and IFN reduced the lysis of Me665/2, but not of K562, by CTL 49 in 18-h cytotoxic assays. Antibodies to TNF alpha and to IFN gamma almost completely inhibited the lysis seen on Me665/2 (but not on K562), in 96-h assays, by supernatants isolated from VSKB-LCL- or anti-CD3-stimulated CTL 49 cells. Taken together, these data indicate that major-histocompatibility-complex-independent lysis of autologous tumor cells and of natural killer reference targets by the same alloreactive T cell clone are activities related at the level of target recognition but distinct at the level of the lytic hit. Thus, efficient lysis of autologous tumor cells results from a complex mechanism based upon direct effector-target interaction as well as on cytokine-mediated cytolytic effects.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2149669     DOI: 10.1007/bf01741719

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  38 in total

1.  The use of hybrid hybridomas to target human cytotoxic T lymphocytes.

Authors:  A Lanzavecchia; D Scheidegger
Journal:  Eur J Immunol       Date:  1987-01       Impact factor: 5.532

Review 2.  Immunotherapy of cancer using interleukin 2: current status and future prospects.

Authors:  S A Rosenberg
Journal:  Immunol Today       Date:  1988-02

3.  Purification and characterization of a cytolytic pore-forming protein from granules of cloned lymphocytes with natural killer activity.

Authors:  J D Young; H Hengartner; E R Podack; Z A Cohn
Journal:  Cell       Date:  1986-03-28       Impact factor: 41.582

4.  Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction.

Authors:  A Anichini; A Mazzocchi; G Fossati; G Parmiani
Journal:  J Immunol       Date:  1989-05-15       Impact factor: 5.422

5.  Characteristics and uses of natural killer cells.

Authors:  T Hercend; R E Schmidt
Journal:  Immunol Today       Date:  1988-10

6.  Anti-tumor activity of class II MHC antigen-restricted cloned autoreactive T cells. I. Destruction of B16 melanoma cells mediated by bystander cytolysis in vitro.

Authors:  T Shiohara; N H Ruddle; M Horowitz; G E Moellmann; A B Lerner
Journal:  J Immunol       Date:  1987-03-15       Impact factor: 5.422

7.  Activation of lymphokine genes during stimulation of cloned T cells.

Authors:  K C Herold; D W Lancki; D E Dunn; K Arai; F W Fitch
Journal:  Eur J Immunol       Date:  1986-12       Impact factor: 5.532

8.  Role of MHC class-I antigens and the CD3 complex in the lysis of autologous human tumours by T-cell clones.

Authors:  T E Roberts; U Shipton; M Moore
Journal:  Int J Cancer       Date:  1987-04-15       Impact factor: 7.396

9.  Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor.

Authors:  A S Chong; P Scuderi; W J Grimes; E M Hersh
Journal:  J Immunol       Date:  1989-03-15       Impact factor: 5.422

10.  Triggering T cells by otherwise inert hybrid anti-CD3/antitumor antibodies requires encounter with the specific target cell.

Authors:  E Roosnek; A Lanzavecchia
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

View more
  5 in total

1.  Requirement of monocytes and T-helper cells during development of tumor cell cytotoxicity in targeted T cells.

Authors:  K A Smans; M F Hoylaerts; M E De Broe
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

Review 2.  Biological significance of autologous tumor-killing activity and its induction therapy.

Authors:  A Uchida
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

3.  Cell retargeting by bispecific monoclonal antibodies. Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma.

Authors:  P Nisticò; R Mortarini; L B De Monte; A Mazzocchi; M Mariani; F Malavasi; G Parmiani; P G Natali; A Anichini
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

4.  Generation and characterization of two human alpha/beta T cell clones. Recognizing autologous breast tumor cells through an HLA- and TCR/CD3-independent pathway.

Authors:  P Nisticò; P De Berardinis; S Morrone; T Alonzi; C Buono; I Venturo; P G Natali
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

5.  Early hematopoietic zinc finger protein prevents tumor cell recognition by natural killer cells.

Authors:  Rosanna La Rocca; Mariateresa Fulciniti; Tadepally Lakshmikanth; Maria Mesuraca; Talib Hassan Ali; Valerio Mazzei; Nicola Amodio; Lucio Catalano; Bruno Rotoli; Ouathek Ouerfelli; Michele Grieco; Elio Gulletta; Heather M Bond; Giovanni Morrone; Soldano Ferrone; Ennio Carbone
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.